Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Rhea-AI Summary

Illumina (NASDAQ: ILMN) on January 6, 2026 announced Illumina Connected Multiomics, a cloud-based research software platform for integrated multiomic and multimodal analysis.

The platform, officially launched last month after input from 40 early access users, can aggregate thousands of multiomic samples, supports single-cell and spatial analyses, includes DRAGEN secondary analysis, and adds AI-enabled variant interpretation via PrimateAI and PromoterAI.

Illumina says the software aims to reduce time, cost, and complexity for researchers and enable reproducible interactive visualizations and scalable workflows for discovery and precision medicine.

News Market Reaction

+4.09%

1 alert

+4.09% News Effect

On the day this news was published, ILMN gained 4.09%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Early access users: 40 users

1 metrics

Early access users 40 users Year-long early access program for Connected Multiomics

Market Reality Check

Price: $145.30 Vol: Volume 2,230,921 is at 1....

normal vol

$145.30 Last Close

Volume Volume 2,230,921 is at 1.41x the 20-day average, indicating elevated interest before this launch news. normal

Technical Price $141.33 is trading above the 200-day MA at $99.20, reflecting a pre-existing uptrend into the announcement.

Peers on Argus

ILMN rose 5.2%, outpacing peers such as WAT (+3.41%), MEDP (+3.25%), and LH (+1....

ILMN rose 5.2%, outpacing peers such as WAT (+3.41%), MEDP (+3.25%), and LH (+1.14%), while PKI was flat and DGX was nearly unchanged. The move appears more ILMN-specific than broad sector rotation.

Historical Context

5 past events · Latest: Dec 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	Investor conference	Neutral	-1.5%	Announcement of webcast participation at upcoming J.P. Morgan Healthcare Conference.
Dec 11	Collaboration deal	Positive	+1.1%	Collaboration and strategic investment in MyOme to support MPH Trial and genomics products.
Dec 11	Correction notice	Neutral	+1.1%	Clarifying details of Illumina’s collaboration and strategic investment in MyOme.
Nov 12	Research publication	Positive	-0.5%	Nature study showing WGS and DRAGEN capturing most genetic signal in common diseases.
Nov 11	Investor conference	Neutral	-0.5%	Webcast announcement for Wolfe Research Healthcare Conference fireside chat.

Pattern Detected

Recent ILMN news often sees modest stock reactions, with mostly aligned moves and one divergence where positive genomic research data coincided with a small price decline.

Recent Company History

Over the last few months, Illumina has highlighted investor outreach, collaborations, and genomic research advances. A Nov 12, 2025 Nature study showed whole‑genome sequencing capturing nearly 90% of genetic signal across 34 diseases, but the stock dipped slightly. A Dec 11, 2025 collaboration and strategic investment in MyOme around AI‑integrated risk models drew a positive reaction. Multiple investor conference webcasts in Nov 2025 and Dec 2025 caused only small moves. Today’s software launch builds on this focus on AI, WGS, and precision health tools.

Market Pulse Summary

This announcement highlights Illumina’s push to offer integrated, AI-enabled multiomic analysis thro...

Analysis

This announcement highlights Illumina’s push to offer integrated, AI-enabled multiomic analysis through a cloud platform that combines transcriptomics, genomics, proteomics, and epigenetics. It follows recent moves in AI-driven genomics, such as collaborations and a Nature study on whole‑genome sequencing. Investors may watch adoption beyond the initial 40 early access users, how Connected Multiomics complements Illumina’s sequencing systems, and any updates on customer uptake or revenue contribution in future filings or presentations.

Key Terms

multiomic, transcriptomics, genomics, proteomics, +4 more

8 terms

multiomic medical

"a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal"

Multiomic describes the combined analysis of different layers of biological information—such as genes, proteins and small molecules—to build a more complete picture of how cells and diseases work. Like viewing a problem from several camera angles instead of one, it can reveal stronger drug targets, clearer diagnostic markers and better predictions of who will benefit from a therapy, which helps investors assess scientific validity, market potential and development risk.

transcriptomics medical

"integrate information across transcriptomics, genomics, proteomics, epigenetics, and more"

Analysis of all the RNA molecules a cell produces, showing which genes are actively being used at a given time—like reading which recipes are being pulled from a cookbook to see what’s actually being cooked. For investors, transcriptomics helps reveal how diseases work, whether a drug is hitting its target, and which patient groups are most likely to benefit, making it a tool for valuing therapies, guiding clinical trials, and spotting diagnostic or therapeutic opportunities.

genomics medical

"integrate information across transcriptomics, genomics, proteomics, epigenetics, and more"

The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.

proteomics medical

"integrate information across transcriptomics, genomics, proteomics, epigenetics, and more"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

epigenetics medical

"integrate information across transcriptomics, genomics, proteomics, epigenetics, and more"

Epigenetics is the study of how environmental factors and experiences can influence how genes are turned on or off without changing the underlying genetic code. Think of it like a dimmer switch for a light, adjusting the brightness without altering the bulb itself. This process can affect health, behavior, and even how diseases develop, which is important for investors interested in long-term trends in medicine, wellness, and biotech industries.

variant interpretation medical

"AI-enabled variant interpretation, using PrimateAI and PromoterAI, removes background mutations"

Variant interpretation is the process of deciding what a specific change in DNA means for health or disease — whether it is harmless, linked to a condition, or of unknown significance. For investors, these interpretations matter because they affect the value of diagnostics, therapies, and regulatory decisions; like reading a change in a product manual, different conclusions can change clinical use, market demand, and company prospects.

differential expression medical

"provide differential expression, marker gene identification, and cell typing"

Differential expression describes when a gene or other biological signal is turned on or off at different levels between two conditions, such as healthy versus diseased tissue or before and after a treatment. For investors, it matters because consistent changes can point to a drug’s effect, a potential biomarker, or a pathway worth targeting—like seeing which lights change brightness in a house when a new switch is flipped, helping decide where to place bets in biotech development.

spatial transcriptomics medical

"For spatial transcriptomics, Connected Multiomics overlays gene expression data on tissue imagery"

Spatial transcriptomics is a lab technique that measures which genes are active and where they are active inside a tissue sample, producing a “map” of cell behavior rather than a single averaged reading. For investors, this matters because those maps can reveal precise disease mechanisms, identify better drug targets, and improve diagnostic tests — potentially speeding development, reducing trial failures, and creating new commercial opportunities in biotech and diagnostics.

AI-generated analysis. Not financial advice.

Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights

SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. As multiomic datasets grow rapidly in size and complexity, researchers need easy-to-use tools to integrate information across transcriptomics, genomics, proteomics, epigenetics, and more. Connected Multiomics addresses this challenge by bringing multiomic data together in a single platform, reducing time, cost, and complexity, enabling scientists to accelerate discovery and advance precision medicine.

Connected Multiomics officially launched last month following a year of valuable input from 40 early access users. At the University of Colorado Anschutz Medical School, oncology researchers used the technology to uncover new insights on melanoma through analysis of proteomic data. Kasey Couts, PhD, co-director of the CU Center for Rare Melanomas said, "I'm not a programmer, but the software is incredibly user-friendly. I don't need an extensive bioinformatics background to use it, which helps my team focus on the biological insights rather than bioinformatics challenges."

"Illumina Connected Multiomics exemplifies how we're transforming the user experience across our software portfolio," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "We are putting the multiomic pieces together on a single platform that is approachable for biologists and powerful for bioinformaticians so they can focus on discovery, not infrastructure."

Simplifying the multiomic analysis experience
Connected Multiomics can aggregate thousands of multiomic samples from Illumina and third-party assays in a single analysis. It provides reproducible results and interactive multiomic visualizations in one integrated, cloud-based analysis environment using industry standard statistical methods and integrated DRAGEN secondary analysis. Additionally, AI-enabled variant interpretation, using PrimateAI and PromoterAI, removes background mutations and points to the most biologically meaningful multiomic signals earlier in the analysis process. AI capabilities will continue to be added to the software.

Fundamental to the solution are the multimodal capabilities. Both single cell and spatial analysis on Connected Multiomics provide differential expression, marker gene identification, and cell typing. For spatial transcriptomics, Connected Multiomics overlays gene expression data on tissue imagery to provide rich spatial context for biological insights.

Illumina is building the most comprehensive multiomic solutions in the industry, anchored on its world-class sequencing platforms for unmatched quality and scale. For research and pharma innovators, these solutions unlock the next wave of precision health discovery, accelerating breakthroughs in biology and drug development.

"Connected Multiomics is an accelerant—breaking down bioinformatic barriers to create a more complete picture of our biology," added Mehio. "We're excited to see what our customers can accomplish when they can unlock deeper biology with a scalable multiomic workflow."

Learn more about Illumina Connected Multiomics here.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; and (ii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-powerful-software-for-connected-intuitive-and-scalable-multiomic-analysis-302653576.html

SOURCE Illumina, Inc.

FAQ

What is Illumina Connected Multiomics and when was it announced for ILMN?

Illumina Connected Multiomics is a cloud-based multiomic analysis platform announced on January 6, 2026 for ILMN.

How many early access users contributed to Illumina Connected Multiomics before launch?

The platform was developed with input from 40 early access users prior to launch.

What data types can Illumina Connected Multiomics integrate for ILMN users?

It integrates transcriptomics, genomics, proteomics, epigenetics and other multiomic and multimodal data, including single-cell and spatial analyses.

Does Illumina Connected Multiomics include AI tools and which ones are named?

Yes; the platform includes AI-enabled variant interpretation and names PrimateAI and PromoterAI as integrated capabilities.

Can Illumina Connected Multiomics handle large sample volumes for ILMN customers?

Illumina states the software can aggregate thousands of multiomic samples in a single analysis environment.

Where is analysis performed and what visualization features does Connected Multiomics offer?

Analysis is cloud-based with reproducible workflows, interactive multiomic visualizations, and spatial overlays of gene expression on tissue imagery.